Kerecis Limited appears in FDA device records as an applicant based in Isafjordur, Iceland, with Skuli Magnusson listed as contact on the K260058 filing and as Vice President (Regulatory Affairs, Quality & Clinical Affairs) in later FDA correspondence. The supplied collection links a single 510(k) record, K260058 for Kerecis Express (50250), with a Substantially Equivalent decision dated October 30, 2026, received January 8, 2026, under product code KGN and clearance type Traditional. That count is an as-of snapshot of the supplied filings, not a measure of total portfolio, sales or safety performance. [1][2][6]
The linked K260058 record
K260058 covers Kerecis Express (50250) under product code KGN, classified as Wound Dressing With Animal-Derived Material(S). The FDA record lists the applicant as Kerecis Limited at Sundastraeti 38, P.O. Box 151, Isafjordur, Iceland, with a decision of Substantially Equivalent and a Summary statement. The review panel is recorded as General & Plastic Surgery, the submission was not reviewed by a third party, and no Predetermined Change Control Plan was authorized. [1][2][6]
The collection summary for the supplied filings shows one 510(k) record and one SESE decision; the explicitly smaller record sample shows the same single SESE entry. Both denominators describe the same one-record set, so no ratio beyond that single filing is supported. [1]
Other documented submissions
An FDA letter dated July 16, 2025 addresses K251845 for Kerecis Marigen Wound Extra Autologous Hydration, Kerecis Silicone Autologous Hydration and Kerecis Parvus Autologous Hydration, with product code KGN and regulatory class Unclassified. The letter describes the devices as lyophilized, terminally sterilized fish-skin devices made of biocompatible, resorbable fish skin from Wild North Atlantic Cod, intended for single use. [7]
A June 4, 2025 letter addresses K243843 for Tendon Protect (50242) under 21 CFR 878.3300, Surgical Mesh, Class II, product codes OWY and FTM. The same document names Kerecis Reconstruct (K202430) as a proprietary device and MariGen Wound Dressing (K132343) as a reference device. A September 6, 2022 letter addresses K213904 for Kerecis Oral under 21 CFR 872.3930, Bone Grafting Material, Class II, product code NPL, classified as a barrier of animal source for intraoral use. [8][9]
Company statements and ownership
Kerecis states on its own website that it develops, manufactures and sells patented fish-skin soft tissue regeneration products from Isafjordur in northwest Iceland, with regulatory approval in the United States, Europe and several other jurisdictions, and that it provides digital tools including artificial intelligence to support insurance billing. The same publisher states that Kerecis is part of Coloplast A/S, described as a global supplier of intimate healthcare products. Those are company statements; the FDA filings identify Kerecis Limited as the applicant, and no supplied source establishes the corporate boundary between applicant and parent beyond the company's own description. [3][4]
Kerecis describes its fish-skin grafts as used in hospital outpatient departments, wound clinics and physician offices and states that they are covered for nearly 200 million Americans. These are the company's own commercial and reimbursement statements, not findings from the FDA records in this set, and no supplied source documents clinical outcomes, certifications or customer counts. [5]
What the record set does not establish
The public documents do not state a headquarters separate from the FDA filing address, do not list customers, and do not provide efficacy results, patient-selection criteria or treatment instructions. Product availability, current instructions for use and any change in corporate structure after the cited dates remain unknown from this set. [3][5][6]
